What percentage of SenesTech's Q1 2026 revenue came from its Evolve fertility-control products, and how does that compare to the company's overall financial performance?

Evolve fertility-control products accounted for 85% of SenesTech's total Q1 2026 revenue. Despite this strong product concentration, the company reported a net loss of $2.1 million—up from $1.7 million in the prior-year period—even as revenue rose slightly to $493,000.

How long are SenesTech's current cash reserves expected to support operations, and what factors underpin that projection?

SenesTech's cash reserves are projected to fund operations into Q3 2027. This outlook is supported by improved gross margins and modest at-the-market equity raises, despite the company's widened net loss and use of operational cash.

SenesTech (NASDAQ: SNES) posts Q1 2026 loss as Evolve drives 85% of sales

May 13, 2026

SenesTech reported a Q1 2026 net loss of $2.1 million despite revenue rising to $493,000, driven by Evolve fertility-control products accounting for 85% of sales. Improved margins support operations through Q3 2027.

Stock Titan

2026-05-12

SenesTech (NASDAQ: SNES) grows Q1 DTC and B2B sales but widens loss

2026-05-12

SenesTech reports Q1 revenue $0.49M, gross margin 68.6% and continued DTC/subscription growth

2026-05-12

SenesTech Inc (NASDAQ:SNES) Q1 EPS Beat Drives After-Hours Stock Surge Despite Revenue Miss

2026-05-12

SenesTech Q1 2026 Earnings Call: Complete Transcript

2026-05-13

SenesTech Inc (SNES) Q1 2026 Earnings Call Highlights: Record Gross Margin